Ask AI

A Switch in Time: State-of-the-Art Strategies for ART Modification in People with Virologically Suppressed HIV

Video
This activity is available for 1.50 CME/CE credit(s).

Released: November 19, 2026

Expiration: November 18, 2027

See Activity Collection

Most people living with HIV in your practice have likely achieved virologic suppression on their current ART and are doing well, which raises the questions of when to change a regimen that is working, and why. The case for ART modification rests on subtle differences in tolerability, metabolic effects, drug–drug interactions, resistance barriers, and modes of administration that can be decisive for a given individual. In this webinar, featuring video from an interactive, case-based symposium, an expert faculty panel works through commonly encountered clinical scenarios to reveal how and why they choose among an expanded array of switch options.

A Switch in Time: ART Modification

Activity Information

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Released: November 19, 2026

Expiration: November 18, 2027

This transcript was automatically generated from the video recording and may contain inaccuracies, including errors or typographical mistakes.

A Switch in Time: State-of-the-Art Strategies for ART Modification in People with Virologically Suppressed HIV

 

Introduction

 

Dr. Chloe Orkin (Queen Mary University of London): It's wonderful to be here with you all to discuss this symposium, which is going to be about A Switch in Time: State-of-the-Art Strategies for Antiretroviral Modification in People Who Are Virally Suppressed. And I'm very happy to be here with my wonderful co-faculty, Professor Monica Gandhi and Professor Dan Kuritzkes.

 

Faculty

 

And you can see where they come from on the slides. And I'm Professor Chloe Orkin, and I've come all the way from London to Washington, D.C., and I'm very pleased to be here.

 

Disclosures

 

So, here are our disclosures.

 

Learning Objectives

 

And our learning objectives are really around navigating clinical encounters so that we can identify opportunities to optimize antiretroviral regimens in virally suppressed people.

 

Think about how to switch - switch effectively in those that are suppressed in order to optimize long-term outcomes, and also to really take into account the new evidence in terms of emerging regimens, and think about how they could expand the options to tailor optimal therapy for everyone.

 

Poll 1

 

So, we'll start with some polls. And the first poll is: How many people living with HIV do you provide care for in a typical week?

 

Is it:

 

A. 1 to 4

B. 5 to 10

C. 11 to 15

D. 16 to 20

E. More than 20, and

F. Not applicable.

 

Please vote now.

 

Poll 2

 

Okay. And the second question: Could you tell us if you are an academic, if you're from the community, or if this is not applicable?

 

Okay, so let us know about your setting.

 

Pretest 1

 

And now we're going to move to the medical pretests, which are: A person living with virally suppressed HIV has had insomnia since starting dolutegravir/3TC and is requesting a switch to a new drug, doravirine/islatravir. Would you recommend the switch?

 

A. Yes; they want to switch, and doravirine/islatravir was noninferior to standard-of-care antiretrovirals for maintaining viral suppression

B. Yes; there is evidence that this switch will improve insomnia

C. No; there is no evidence the switch will improve insomnia, and

D. No; switching just because the person wants to is not worth the risk of losing viral suppression

 

Vote now.

 

Okay. So, most of the audience said they want - said yes, they want to switch, and - and doravirine/islatravir was noninferior to standard-of-care antiretrovirals for maintaining suppression. But about 8% of people felt that switching because the person wants to is not worth risk. And other people had other perspectives on the issue of insomnia. We'll find out more about this during the course of the symposium and answer this question again later.

 

Pretest 2

 

So, for pretest two, a person living with virally suppressed HIV is receiving darunavir/ritonavir + FTC/TDF and has archived resistance mutations, and the mutations are M184V, M41L, L210, and T215Y. And this is based on a prior episode of virological failure. What would you recommend if they want to take a single daily pill with as few drugs as possible and no food restrictions? Vote now.

 

A. bictegravir and lenacapavir, BIC/LEN

B. Doravirine/islatravir, DOR/ISL

C. Dolutegravir/3TC

D. Any of the above.

 

Vote now.

 

Okay, so we've got quite a split. We've got about 35% for BIC/LEN, 40% for doravirine/islatravir, nobody for dolutegravir/3TC, and some people believing any of the above, and we'll go into this a bit later.

 

Pretest 3

 

And pretest three: For people living with virally suppressed HIV, I regularly discuss whether their current regimen is still the best option for them.

 

A. Strongly disagree

B. Disagree

C. Neither agree nor disagree

D. Agree, and

E. Strongly agree.

 

Vote now.

 

Okay. So, 50% are saying that they agree, 25% are saying they strongly agree, and 20% are saying they neither disagree or agree. Right. So, we'll come back to these later on.

 

Switching Antiretroviral Therapy

 

But now, for everybody that's here in the room and for all of you that are online, I'm going to give - say some words around switching antiretroviral therapy.

 

Why Revisit ART During Viral Suppression?

 

So, why revisit antiretrovirals during viral suppression? Well, as we've just seen, some of the reasons could be about simplifying treatment. And that can mean simplifying in terms of pill burden. It can mean food. It can mean dosing requirements.

 

It's really important to consider tolerability and to think about long-term safety.

 

It's important to reassess fit as things change, as people develop comorbidities and people develop organ dysfunction. And also, we always have to consider liabilities for drug-drug interactions.

 

But it's also equally important to consider priorities. People's lifestyle, privacy, and also cost.

 

IAS-USA Guidance on Switching ART With Viral Suppression

 

So, what does the IAS-USA Guidelines say on switching antiretrovirals in the context of viral suppression? So, what it says is that people with HIV and viral suppression may be receiving regimens that are no longer recommended due to short- and long-term adverse events, inconvenience, regimen complexity, anticipated drug-drug interactions, progressive kidney disease, risk of cardiovascular disease, or cost.

 

So, switching antiretrovirals to one of the recommended initial antiretroviral regimens in these circumstances is frequently the optimal strategy, provided that virological suppression can be maintained. And this was in 2025. So, that's - those were the guidance at that point.

 

Ask Us Europe: Treatment Review Is Not Routine

 

So, I think it's really important to say that as clinicians, you know, we all have our consultations. And I think - I think a lot of us think that we have these conversations with people. But I led a study recently called Ask Us Europe, and I'll talk about it a bit later. But basically, it was across 18 European countries. We had nearly 2,000 people responding to a survey.

 

And what the survey was about is what's actually taking place between the clinician and the person living with HIV. And we asked people if they could recall ever having had a discussion about their treatment, a treatment review discussion. And 81% recalled a discussion ever in their lives about their treatment. But only 41% recalled a discussion within the past year. And this is across 18 different European countries. And the findings were very, very faithful across the different countries. So, it was really a widespread finding.

 

And what we found also is that respondents over the age of 55 were less likely to report a recent - report recalling a recent treatment review discussion.

 

HIV Treatment Is NOT One-Size-Fits-All

 

So, it's important to recognize that HIV treatment is not one-size-fits-all. And shared decision-making is increasingly focused on something as a very important parameter and something that we really should aspire to during consultations. So, it's shared decision-making and also offering choice as sort of really critical aspects of the consultation, particularly for people that are virally suppressed because they could actually have been on their treatment for a long time.

 

And from my perspective, this involves sort of three really important steps. And that is explaining the features and the considerations of the switch regimen options, and then really confirming that the person shares the understanding that you have, and also listening to what the person is really looking for in their treatment. And it - ultimately, it's about sharing that power. It's about making sure that you have the knowledge, you - you pass on the knowledge, you share the informations in order to enable a decision from the person that is right for them and what will fit best with their lives.

 

Questions to Ask Patients About Their ART Regimen

 

So, some questions that one could ask about people's regimens to sort of prompt a discussion like this would be really about thinking about: is this regimen still the best regimen for them? So, you could ask about how satisfied they are. You could ask if they think the regimen is working for them. You could ask about challenges or simply if there's anything you wish was different about the regimen. Because I think one thing that we definitely found in the study is that different people, you know, really had different degrees of ability to actually navigate and introduce these discussions. In many cases, the discussions were only had if the healthcare provider initiated the discussion. Some people feel very confident and will come in and say, "Actually, I'd like to change my treatment," but not everyone is in this position.

 

Available Switch Regimens

 

So, let's think about what the available switch regimens actually are.

 

The Switch Landscape

 

So, we've had a very rich switch landscape for some time. We've had bictegravir/FTC and TAF. We've got doravirine-based therapy. We know we've got darunavir/cobicistat/FTC/TAF as a single-tablet regimen. We've got two-drug dolutegravir/3TC regimen, dolutegravir/ rilpivirine. And we also have injecting - injectable, long-acting cabotegravir/rilpivirine.

 

But in 2026, we've got two newly licensed options, and that's bictegravir/lenacapavir and doravirine/islatravir. And we also have an investigational, once weekly oral therapy, which was presented this year, islatravir/lenacapavir. It's not yet licensed, but it's in phase III. And then we've got a whole raft of other regimens out there. So, we've got islatravir/ulonivirine, which is in phase IIb, moving forward into phase III studies. We've got a long-acting cabotegravir dosed asynchronously with lenacapavir, which there are some studies looking at that. We've got long-acting cabotegravir dosed asynchronously with lotivibart, which is also known as N6LS. And then we've got lenacapavir dosed together with, here we go, TAB + ZAB. And I'm not even going to try at this stage of the evening in the UK for me. And that is actually a six-monthly synchronous regimen that those are being investigated.

 

DOR/ISL

 

So, what about doravirine/islatravir? So, this is now FDA-approved. It's a once-daily tablet combining doravirine, which we know is an NNRTI, with islatravir, which is the first-ever NRTTI, so a translocation transcriptase inhibitor. And we saw two switch studies, the 051 and the 052 studies, which looked at switching people who were virally suppressed. In the 051 study from any oral regimen, and in the 052 study, away from bictegravir/FTC/TAF. And these were in adults who were virally suppressed, who didn't have any history of virological failure or any disclosed history of virological failure.

 

And both studies showed that they were noninferior to the comparator in terms of maintaining viral - viral suppression, and it was approved in April by the FDA.

 

BIC/LEN

 

Then we've got BIC/LEN, which is also approved. It's a single tablet, including bictegravir, which is an integrase inhibitor, with lenacapavir, our first capsid inhibitor. And we saw the ARTISTRY-1 and 2 studies presented this year at CROI. And they looked at switching away from either complex antiretroviral therapy - and we'll see this a little bit later - or switching away from B/F/TAF in the ARTISTRY-2 study in people that were virally suppressed. And once again, noninferiority was demonstrated, and the drug was licensed in August.

 

Comparing Newest Approved Options: DOR/ISL and BIC/LEN

 

So, if we think about these two drugs for doravirine/islatravir, what we've seen is that there was no metabolic or weight changes versus standard antiretroviral therapy, unless you are removing a weight suppressant drug like TDF or efavirenz. There was no dose adjustment needed if the eGFR is greater than 30, and it's of course always important to assess for drug interactions.

 

For BIC/LEN, there were no weight changes versus comparator in the clinical trials. There was no dosage adjustment needed for people who had creatinine clearance of greater than 15. And of course, one must assess always for drug-drug interactions in association with - with LEN.

 

Investigational Option With Phase III Data: ISL/LEN

 

So, the weekly oral therapy that I mentioned that was very exciting. We've got islatravir, the NRTTI, together with lenacapavir. And we saw the ISLAND or ISLAND 1 and 2 studies evaluating switches to ISL/LEN from BIC/F/TAF or from standard oral therapy. And we saw across both studies that noninferiority was demonstrated.

 

Regimen Optimization: Keys to Success

 

So, when we think about regimen optimization and the keys to success, obviously, first and foremost, what we really must do, we must maintain viral suppression. So, the regimen needs to be at least as good, if not better. And this applies to both safety, efficacy, and tolerability. And this, we also have to consider the barrier to resistance. And that means we do have to think about previous regimens in terms of prior virological failure, and also about what might be their known or suspected resistance and intolerances, and consider DDIs and comorbidity.

 

One of the key features of the future pipeline is that almost every agent in the future pipeline, almost every combination that I've told you about, is, in fact, a two-drug combination. And none of these drugs actually contain tenofovir. So, this means that we're losing our two-drug protection in terms of hepatitis B, both in terms of stopping reactivation and also stopping new infections. So, it is important to bear this in mind and make sure that we are aware of this in order to maintain viral suppression and achieve good outcomes.

 

Interpreting Resistance History

 

When we are thinking about prior resistance, it's important to use caution if we're switching, if there's full - if there's a full treatment and resistance history unknown. So, if we're getting a patient from somewhere else and we don't really know what's happened in the past, because what we know is that once we - once there is a resistance mutation, it's archived and it remains present. And one has to bear in mind that if one has - if someone has experienced virological failure on a low genetic barrier regimen like an NNRTI, 3TC, raltegravir, or elvitegravir, then the virus maintains this memory, and this can happen - this can lead to treatment failure.

 

So, with a history of multiple treatment failures and incomplete resistance history, a proviral DNA genotypic test can be considered, and if it shows something, that's very helpful, but it doesn't always reveal everything, and sometimes it can miss things. So, actually, it can lead us astray rather than helping us. But that's - which is why it's a research tool and not considered as a main treatment in guidelines.

 

Case 1

 

So, I'm going to move to Case 1. And Case 1 is, I think, you Monica, was it. Yeah.

 

Dr. Daniel Kuritzkes (Harvard Medical School): Yes, that's right. Great. If you just hand me the clicker. That's terrific. Well, thanks so much for that terrific overview, Chloe. Let's move on with our first case now.

 

Case 1: Freedom From Daily HIV Pills

 

So, this is a 34-year-old man who was diagnosed with HIV nearly a decade ago, back in 2019. He's currently on daily oral therapy with bictegravir/FTC/TAF, with a virus load that's been undetectable since starting on treatment.

 

His BMI is - puts him into the moderately obese category at 31kg/m². He, not surprisingly, also has hypertension and hyperlipidemia, for which he takes atorvastatin and losartan. And in terms of his hepatitis B virus status, that Dr. Orkin just highlighted the importance of, he has evidence of immunity to hepatitis B because he's surface antibody positive, but he's core negative. So, he's probably never been infected with hepatitis B virus. He probably was vaccinated against it.

 

And he's asking for freedom from daily oral - from daily therapy. It's a reminder of his HIV status. And he would really prefer to be on something less frequent.

 

Poll 3

 

So, would you continue oral ART or offer him long-acting cabotegravir + rilpivirine as injectable therapy? There are three choices here. You can either:

 

A. Continue him on oral ART

B. Offer him long-acting injectable CAB + rilpivirine, or

C. You're unsure

 

We'll give you a little bit of time to think about that and respond.

 

So, a large majority of the audience would offer long-acting CAB + rilpivirine. About 13% would continue him on the same therapy, and a small number were unsure.

 

Before we get into more of the details here, let me ask Chloe: how does his BMI of 31 influence your consideration of putting him on long-acting CAB + rilpivirine?

 

Dr. Orkin: So, in my mind, it doesn't, because there's, firstly we're going to, I think, discuss a multivariable analysis that was done, and we will show that to you. But what I would definitely say is that the clinical cohorts are the large cohorts, such as the OPERA cohort, which is, you know, several years ago, shown already an early analysis looking at people with high BMI versus low BMI showed absolutely no difference in terms of viral suppression. There have been other clinical cohorts which have reported. The Maguire cohort has reported with quite significant BMIs over 40. And I think what's very clear is we do need to use the longer needles. And I think what's really interesting is that, you know, everything that we know about BMI and any risk of high BMI, it comes from the initial trials, the registrational trials, the FLAIR, the ATLAS, the ATLAS-2M. And in those trials, not all of the clinicians actually used the long needles. So, any - so, what we know is based on people not actually doing the best possible practice. So, in my mind, on its own, it doesn't worry me. Okay? If it's associated with something else, that it starts to become important.

 

Multivariate Analysis of LA CAB + RPV Risk Factors for CVF

 

Dr. Kuritzkes: Well, that's a great segue to this next slide here, which summarizes the results of this multivariate analysis that we were both a part of. And this pooled data from three registrational trials: FLAIR, ATLAS, and ATLAS-2M, and found there were three baseline risk factors for confirmed virologic failure among people switching to long-acting CAB/rilpivirine. These included having a high BMI, having HIV that was subtype A6 or A1, but it was really A6, or having archived rilpivirine resistance-associated mutations. And what you can see is that overall, the failure rate was incredibly low, just 1.5%. Those who had none of these factors, only 4 out of nearly 1,000 people who had virologic failure, and having just one factor made it slightly more frequent, 2%. But it was really if you had two or more factors that you were at substantial risk of virologic failure. So, Dr. Gandhi, do you use these? Would you recommend this drug if there is just one risk factor?

 

Dr. Monica Gandhi (University of California, San Francisco): Yeah. So, we - I totally agree with you. The weight is a nonissue anymore because of all the real-world data. But why was it even theoretically an issue is because it may have lowered cabotegravir concentrations, but that longer needle gets you past into the intramuscular space. So, we're done with that. We just use the longer needle. Then, in terms of having A6 or A1, the CARES study, which was a trial done in countries in Africa, essentially looked at, you know, switching over to long-acting ART if you're suppressed and there was no issue with A1. So, like you said, that's done. We're done with A1. And A6 is typically we're not seeing people with A6 from Eastern Europe.

 

So, the third is having rilpivirine-associated RAMs. So, we don't, in our practice at Ward 86, do archive genotyping. There have been some clinic centers who said, "If I'm switching over, I'm going to do archive genotyping." This was a decision we made because of all the discordance between archives and what you see historically. So, all we do is look at historical RNA genotypes. And then if historically there's been rilpivirine mutations or - or integrase resistance mutations that will confer resistance to CAB, that's when we don't use it. So, we're just focusing on that one risk factor and the historical RNA results.

 

Dr. Kuritzkes: Yeah. Thanks. I'll make two quick points. One is, actually, looking more deeply into the data from FLAIR, ATLAS, and ATLAS-2M, it turns out that virtually all of the people who had - who failed with a high BMI also had rilpivirine RAMs. There were very few people who were either just obese or just had RAMs and had virologic failure. So, you really did need those two together. And you can imagine, well, if you're maybe getting slightly lower levels because you have a high BMI and maybe you're not using the right needles, and you also have preexisting resistance mutations, you're more likely not to have adequate drug levels, but having just one or the other alone wasn't - wasn't sufficient.

 

The other point is that on Friday, there's going to be an oral abstract presentation that talks about the use of CAB/rilpivirine in people who's - who had BMIs of 30 or greater, but had no other risk factors for treatment failure.

 

Chloe, let me ask you, how do you discuss these factors as part of a shared decision-making discussion since you raised that in your presentation?

 

Dr. Orkin: So, I - I do actually discuss them. So, I say to people that switching to injectable cabotegravir/rilpivirine, if you're on an integrase - modern integrase regimen, either dolutegravir/3TC or bictegravir/FTC/TAF, you would not expect to have virological failure at all if you carry on your oral treatment as long as you take it. If you switch to injectable, the risk is very low. Across all of the studies, it looks like it's around 1- between 1% and 2%, probably closer to 1%. But that's not nothing. But there are certain things that we know about that make it more likely. And then I say, you know, obviously, if you've previously had the situation where you may have stopped your treatment or experienced virological, you know, we don't know. If we can find these things on proviral DNA, rilpivirine RAMs, we find evidence of resistance. And then I say about the particular subtype of virus, you know, the A6 subtype, you have one of these things plus BMI, or if you have one of these two things together, then your risk goes up significantly. So, I explain, if you've got two factors, then the risk is, you know, is much higher.

 

And then I get them to explain back to me what I said. Have I said it's the same as taking oral therapy? Is there a higher risk? How high is it? And, you know, I get some sort of an answer back. And then based on that, I - we do it again until we - until we're both on the same page that they understand that there is some higher risk, but it's not a high risk, and that the risk depends on things about them and - which I'm telling them, you know, whether they're on the high end or low end.

 

Dr. Kuritzkes: Great. And I'll just make one other quick point, which is that although Monica pointed out that it's very rare for us to see people with HIV due to - A6 here in the United States, A6 has been spreading throughout Europe because even though it was really predominantly seen in Eastern Europe, with all of the disruption that's occurring in Eastern Europe, there's been huge migration, and now A6 is becoming much more prevalent throughout Europe. Let me turn this over now to Dr. Gandhi, who can take us through the next case.

 

Case 2

 

Case 2: Patient on INSTI With Insomnia

 

Dr. Gandhi: Okay, so case number two is an 80-year-old man. He was diagnosed with HIV pretty recently and actually started on dolutegravir/3TC, an easy-to-take regimen. But in his particular case, he didn't have any - he had a few things to consider. He does have chronic renal impairment. He has a mechanical heart valve, which means he's on warfarin, not DOACs. And he has hypertension and hyperlipidemia. And his GFR is 30. And he is immune also to hepatitis B.

 

Switch to DOR/ISL From Oral ART: Study Design

 

So, after a while, he came in, and he said, "Well, I just - I don't like the - the INSTI." He didn't say INSTI, but he said, "I don't like the dolutegravir." And specifically getting into it, it was insomnia with that particular combination. And in fact, he came to me, you know, like in - right. You said that doravirine/islatravir was approved in April, and he had read up, and this was in May, saying, "What about this other pill?" So, the insomnia just kind of digging into that, he - I just do wanna say that it was bothersome enough and it was new enough that when I offered him other integrase-based regimens, he was worried that it was the dolutegravir because he had read in the package insert that that's very, you know, there can be some insomnia with that agent. And that's why he was specifically asking about getting off an INSTI, which is, of course, first-line therapy worldwide as INSTIs. So, why, when we think about BIC/LEN, which we'll get into. That's an INSTI. Why would we go to doravirine/islatravir? In this case, he wants to avoid an INSTI, but let's go over the data on what led to its approval.

 

There are actually three major trials. We're not going to talk about the treatment-naive study, but that is something to look at. And - and a couple of people didn't do great if they started with very high viral loads. But that's not in the package insert because this was actually approved based on two switch trials.

 

So, the switch from doravirine to islatravir, whenever you see now switch trials, they're even going to switch from BIC/TAF/FTC, or they're going to switch from whatever they're taking. And so, in this case, in his particular case, it's whatever he's taking, he's taking dolutegravir/3TC, but these were individuals who were on two- or three-drug oral ART. And importantly, they can't have had an active hepatitis B infection because none of these new regimens were talking about CAB/RPV included, or BIC/LEN covers hepatitis B, and also no prior treatment failure to get into the criteria of this trial. And of course, no known doravirine resistance. So, say they had, you know, a passed-on transmitted acquired NNRTI mutation.

 

So, then the design was just staying - switching on - staying on their oral ART or switching over to doravirine/islatravir.

 

Switch to DOR/ISL From Oral ART: Wk 48 and Wk 96 Virologic Outcomes (FDA Snapshot)

 

And the 96-week results were presented at CROI this last time, and the 48-week results are published. And so, we have data from both. And the 96-week and the 48-week results look good, meaning really high rates of maintenance of virologic suppression of switching over to doravirine/islatravir.

 

So, then it actually becomes an issue that we're going to discuss is why would you want to use this - this agent? So, first I'm going to ask this question, and then we're going to discuss.

 

Posttest 1

 

So, this was what Chloe had asked you, but this is now the case. You have the context. He has insomnia. He wants to switch. Would you recommend that switch?

 

And the answer is:

 

A. Yes. Go ahead. It's noninferior. He fits the criteria of the trials, or

B. Yes; it improves insomnia

C. No, there's no evidence about that, or

D. No, I don't want to derail anything by switching

 

So, please vote.

 

So, there was more people essentially that went to saying yes, I'll switch because now we know the switch data. And I will say that that is actually what happened in this particular patient case.

 

Rationale

 

And there was a couple of other factors which we're going to discuss that led to it because you always have to think about what would be an advantage of doravirine/islatravir. One is renal because he did have chronic renal insufficiency, and then one is actually that he was on warfarin, and there's drug-drug interactions with that with anything that's a CYP3A4 inhibitor. So, we, you know, we obviate any issue there. Lenacapavir would have more. So, this is - this is something to discuss.

 

So, actually, I wanted to ask the two of you: would you have switched to this? I - I know it's out in the United States, actually. I don't know if it's there yet in the UK, but yeah, that's what I thought. But would you switch to it? And yes, he had found it, but what were the advantages that you think that you would have switched?

 

Dr. Orkin: I mean, I think I would always discuss the insomnia first and try - and discuss sleep hygiene and try and understand if there are any other factors that could be improved. But I think ultimately, if, you know, I think believing the person is really important, if he feels - if he associates it with the drug, I would, you know, that's a side effect, and I would be very open to switching him. Unfortunately, we don't have doravirine/islatravir, but for all the reasons we've seen, I would be very happy to - to use it if we did have it. Yeah.

 

Dr. Gandhi: Yeah. And the renal for me also, and the drug-drug interactions pushed me over. So, what do you think, Dan, on - because there are some other options.

 

Dr. Kuritzkes: Yeah. So, you know, I think interestingly, in today's New York Times, there's an article in the health section about 10 drugs that may be messing with your sleep. So, it's not just integrase inhibitors. And so, I think it would be important to review with the patient what else that he's taking might be contributing to the insomnia. But at the end of the day, if the patient is convinced that it's the integrase inhibitor that's contributing to the insomnia, you know, and there are alternatives that are going to be just as effective virologically, then, you know, I think it's perfectly reasonable to make the switch.

 

The only other non-integrase inhibitor-based regimen that I could think of here - well, I guess there would be two, potentially. You could put them on rilpivirine. He doesn't have any NNRTI resistance mutations. So, you could put him on rilpivirine/FTC/TAF. That would be going back to a three-drug regimen. You could also consider doravirine - I misspoke - rilpivirine/FTC/TAF or doravirine/3TC/tenofovir, but that would be tenofovir disoproxil fumarate with the - all those technically within the label. With his eGFR of 30, I'd be a little reluctant to put him on the older formulation of tenofovir.

 

Dr. Gandhi: I think that's a good point, because that was actually even why I put him on dolutegravir/3TC to begin with; I really did want to avoid tenofovir because he had - he's 80, and then he had - even TAF, I was anxious to avoid because he had so many accumulative risk factors for renal insufficiency. He was just going to keep on getting worse. So, I think that's a really good point that I was avoiding both, and then dolutegravir/rilpivirine would have dolutegravir because of the insomnia. So, I it - it kind of honed in on this as - as the choice, but - but we're going to talk, you know, BIC/LEN was not out then, but even if it was the BIC is an INSTI and maybe there was cross with that. And then lenacapavir, you have to say, does have more drug-drug interactions with warfarin. So, I think that was great.

 

Case 3

 

So, then we'll go to something more complicated because it's always good to sometimes bring in resistance. Let's do it.

 

Case 3: Simplifying a Complex Regimen for Extensive Resistance

 

So, a 78-year-old man, he's had HIV for a long time and had a lot of prolonged viremia on those harder-to-take regimens. Tenofovir came out in 2001, and the first integrase inhibitor came out, raltegravir, in 2008. So, the period between 2001 and 2006 was kind of hard because there were just lots of pills, and it could be more difficult. And there were the old thymidine analogues, and all of that meant that he actually had viremia during that time, which is, of course, going to lead to why he had all this resistance.

 

He's now because he has this resistance. And the specific resistance he has is he has TAMs; he has actually three TAMs there. And then he has in the NNRTI class, K103N; he's probably been on nevirapine in the past, but then why doesn't anyone see efavirenz. And then he has two darunavir associated mutations and we think you can't have 11. But two is you start thinking that there's reduced susceptibility or at least sometimes we double the dose. So, all of that means is he was on a kind of complicated regimen at this point because of wanting those two darunavir-associated mutations. He wasn't on darunavir/cobicistat; he was on darunavir/ritonavir. He was BID because that gets you over those two mutations. He was on BID maraviroc, and then once daily, because luckily, he didn't have any INSTI mutations, dolutegravir. But it's still lots of pills. So, that's, you know, six pill - yeah. One, two, three, four, five, six, seven pills. And then he had - he was undetectable. So, then he comes in, and he says - he's also hepatitis B-immune. He says, "Is there anything that I can do that's easier than this? Because this is a lot of pills."

 

And there's really two things to discuss. Maybe - maybe though, before I, like do the data, or should I do - I mean, I think it would be interesting to hear your thoughts, actually.

 

Dr. Orkin: Yeah, yeah.

 

Dr. Gandhi: Please tell me. Yeah, Dan, what do you-

 

Dr. Kuritzkes: Yeah. So, I certainly think that he's on more drugs than he needs. I think, you know, we know from a number of studies, including the DAWNING study and the NADIA study now, which was studies of comparing integrase inhibitors to boosted protease inhibitors in people who had failed first-line therapy with an NNRTI where there was extensive nucleoside resistance that both regimens did extremely well.

 

Now, in his case... Maybe just back up one before we get to the poll. Yeah. In his case, darunavir/ritonavir may not be as effective by itself compared to dolutegravir because he does have darunavir resistance mutations. But I don't see any reason why this person wouldn't do just fine on a regimen of dolutegravir with 3TC or FTC and TAF, or on bictegravir/FTC/TAF despite the presence of these TAMs because of the data that we've seen from - from other trials. And then there are, along the same lines, a number of the other two drug regimens that we've discussed could be perfectly appropriate for him, although there are some subtleties here. He's obviously had prior treatment failure, and several of the two-drug regimens were studied as switch only in people who at least never confessed to having had prior treatment failure. So, for example, dolutegravir/3TC, virologically, there's no reason why it wouldn't work. But he would be off-label because he's had treatment failure. Likewise, doravirine/islatravir. He doesn't have doravirine NNRTI resistance mutations, and bictegravir/lenacapavir, as in the earlier case, could be a good alternative for him here because he has no integrase inhibitor resistance and obviously no prior capsid exposure. And BIC/LEN was studied in people just like this who had - who were on a complex regimen.

 

Dr. Orkin: Yeah, no, I agree. I think it would be interesting to see what the audience thinks. The next slide.

 

Poll 4

 

So, you've heard us while we're talking; why don't you type your responses? Let us know what you think. It's not so much a poll. No, it's not a poll, I don't think.

 

Dr. Kuritzkes: Right. This is a free text response.

 

Dr. Gandhi: One thing I would say about the INSTI-based regimens is though I agree that BIC/TAF/FTC is likely to work, I will say we have more data on dolutegravir/TAF, you know, and two NRTIs in the context of NRTI resistance: we have NADIA, we have DAWNING, we have the D2EFT study. We just have a lot more data.

 

The data on BIC/TAF/FTC in the context of NRTI resistance is called the BRAAVE 020 study. And then there's also something called GS-4030. And these are the two study names where people are switched over when they're suppressed, and they have a history of these mutations. So, that's not as stressful, I think, as the NADIA study, where you had frank resistance, and then you saw that dolutegravir really held it up. So, I think there are going to be equivalent, but I'm just pointing out that the data, I think, is more with - with dolutegravir.

 

And then with darunavir, like one other comment on that. I totally agree with you. Darunavir would have been great by the EMERALD study. The EMERALD study is when people were on boosted PIs and two NRTIs, and they were switched over to dolutegravir/cobicistat/TAF/FTC, and they did great, even when they had lots of resistance in their background. There was 38% M184V and lots of three TAMs and even some K65R. But in this case, we have two dolutegravir mutations, which make that not ideal.

 

So, this is getting us into some of these new things. And it sounds like you also thought some new things. And this is why this is such a great program because we're talking about new drugs. Actually, people said BIC/LEN, which we get to talk about next with the data. And I think that's great. Some people said BIC/TAF/FTC. That could work. Some people said CAB and LEN, which I think is a great idea because Chloe called that an emerging possibility. I mean, since they're both approved, why not? Can we put them together? And then someone said doravirine/islatravir, which is not unfair, except supposedly the trials like we just presented, you know, no history of virologic failure. But the archived mutations we will talk about. So, I think these are all excellent, and it leads us into the next points of discussion.

 

Retrospective Case Series with LEN + CAB at Ward 86

 

So, we did want to talk about lenacapavir/cabotegravir not as approved regimen not studied in clinical trials yet. We're waiting for those clinical trials to launch. They will launch. There's been some NIH disruptions. But - so we have case series. That's what we can go off of. What is it? Does it make sense? It completely makes sense because you're putting an INSTI and a capsid inhibitor together, and they both happen to be individually approved for long-acting ART. And so, why not put them together? It's kind of like BIC/LEN, but they're both long-acting, especially in someone who needs long-acting.

 

So, the largest case series was just published, you know, three weeks ago and two weeks ago. And this is people at Ward 86, the clinic in which I work. And there's - we had 46 people who we decided to put on CAB and LEN; a lot of them had NNRTI resistance, which is a reason to do it. Rilpivirine resistance. He has 181C, which will slightly reduce rilpivirine susceptibility. And these 46 people, 20 - more than half started with viremia, and they all almost all had NNRTI resistance, like I said, and sometimes we'd give them rilpivirine too if they didn't have NNRTI resistance. And everyone got suppressed if they had viremia by 15 weeks, and by 100 weeks, 100% of them were virologically suppressed.

 

So, proof of concept. Of course, these are good two powerful drugs, and it's going to likely work, and we are going to do clinical trials.

 

ARTISTRY-1: Switch to BIC/LEN From Complex ART

 

And then the data on - on BIC/LEN. There's actually two big trials, but we're not going to go over ARTISTRY-2. ARTISTRY-2 is switching over from BIC/TAF/FTC. That's easy. But this was actually a much more complex patient population - participant population presented by Dr. Orkin here. So, this is a multicenter, open-label, it was active-controlled. And importantly, these were - participants that had a lot of complexity in their past. They were a median time of being - living with HIV is 28 years. They had had lots of treatment experience and lots of - and this was both on historic resistance testing, lots of NNRT- NRTI resistance in the past like he did 68%. Some NNRT- lots of NNRTI resistance. Even some PI resistance like this participant has. And I will just draw your attention to the important thing is they were on lots of regimens, so he's on way more than four pills even. And that's true. 22% of these participants were on four pills or more, and certainly so many were on two pills or more. So, it meant this is exactly this particular - these participants reflected our patient.

 

ARTISTRY-1: Wk 48 Efficacy

 

And what did the results show switching over from their complex ART to BIC/LEN out to 48 weeks? Really high rates of maintenance of virologic suppression. They were all virologically suppressed, and they were maintained. It was not - BIC/LEN was not inferior. And in some subanalyses, if you were on PIs especially, it improved your lipids to go over to BIC/LEN, didn't improve hemoglobin A1c or anything like weight, and there's some data here at the conference about that.

 

So, it looks like you could get someone who had that many pills on one pill, and that's kind of an amazing thing. And this is where I'm using BIC/LEN; is in a patient population like this, don't you think?

 

Dr. Orkin: Absolutely. And rather poetically, I'm told that it's the smallest of all of the single-tablet pills, which it actually feels like a lovely - lovely gift to people who time has left behind. Because actually, whether there are regimens, we - I mean, as Dan has said, there are - it may have been possible to switch people to receive bictegravir/FTC/TAF, or to have had dolutegravir with TAF or TDF and FTC or whatever, but no one did it. And I think the thing is that this regimen has been studied robustly, okay, in people with significant complexity, and it has withstood this. And because this has happened in this particular population, it gives the confidence to actually use it. And I think it's a very powerful data. And this population was a population unlike any clinical trial population that I've ever seen. The median age was 60, and most people had at least one comorbidity. Most people had at least two comorbidities. They were taking lots of other drugs. 80% of them had some degree of resistance. And it worked. And I think, you know, when I got off the stage from giving the presentation, the first person to speak to me was a trial participant. He came up to me, and he said to me, "I had terrible diarrhea. I couldn't leave the house until I went onto this regimen on - on my PI, and it made a big difference to my life." And I think - I think it's - it's easy - it's easy for us to get focused on the viral load as the most - single, most important thing. But, you know, I think the whole point about living with HIV is living bit.

 

Posttest 2

 

Dr. Kuritzkes: So, that brings us to our posttest. This case is - the capsule here is slightly different than the patient we just discussed. But this is a person living with virologically suppressed HIV who's receiving boosted darunavir with FTC/tenofovir and has archived resistance mutations. Here, there is a 184V in addition to some of the TAMs. And this is all based on prior virologic failure, or these mutations are here because the - this patient had a history of prior virologic failure.

 

So, what would you recommend if they want to take a single daily pill with as few drugs as possible and no food restrictions? And the - the options offered here are.

 

A. Switch to BIC/LEN

B. Switch to doravirine/islatravir

C. Switch to dolutegravir/lamivudine, or

D. Any of the above.

 

So, we'll give you a moment to think about this.

 

And not surprisingly, perhaps, nearly 70% of you chose that BIC/LEN would be an appropriate choice or the best choice. But interestingly, nearly a quarter thought any of the above would be appropriate. And we can have a little bit of debate about this.

 

Rationale

 

But the key point, as I mentioned a little bit earlier, is that the current indications for switching to doravirine/islatravir or to dolutegravir/3TC are in virologically suppressed individuals who have not had a prior history of treatment failure, and this individual clearly had prior treatment failure. The debatable part, which we'll get into in the next case, is whether the presence of pre-existing resistance mutations, specifically the 184V and the TAMs, have any adverse effect on doravirine/islatravir. And we'll get to that in a moment. So, I won't belabor the point right now, but because the person has a documented history of virologic failure, it would be off-label to consider the use of doravirine/islatravir or dolutegravir/3TC.

 

Case 4

 

So, let's go ahead with our fourth case.

 

Case 4: Simplifying ART With Resistance, Variable Past Adherence, and HBV

 

These cases are becoming more and more complex as we go. So, this is a 40 - a 53-year-old woman who was diagnosed with HIV after having pneumocystis pneumonia 20 years ago and has been through a variety of regimens, including efavirenz-based therapy, one of the earlier-generation integrase inhibitors, cobicistat boosted elvitegravir, and she had variable adherence to those regimens, was out of care for a period of time, and at the time that she re-entered into care two years ago, had a virus load of over 400,000, had quite advanced disease with a CD4 count that was below 40 and at that time had several resistance associated mutations, including the M184V mutation for FTC and 3TC and then a couple of NRT mutations, the k70N and the Y115F, and then also an NNRTI resistance mutation, the K103N mutation.

 

Importantly, this person also had evidence of having acquired hepatitis B virus. She was not only hepatitis B surface antigen-positive, but had a hepatitis B viral DNA of over 2 million copies per mil. So, given the resistance mutations and the presence of hepatitis B when she returns to care in 2024, she was restarted on treatment with a combination of bictegravir/FTC/TAF, which were going to be active against her HIV. But with the sort of belt-and-suspenders approach of adding boosted darunavir because of the uncertainty in the presence of some of these resistance mutations that might have an effect on FTC and TAF, the moderately high virus load, to just be sure that - that she would be virologically suppressed. And she does indeed achieve virologic suppression. She'd be quite happy to continue on oral therapy, but maybe not such a complicated oral regimen.

 

Poll 5

 

And so, what would you recommend? And we'll ask you first before we discuss this time. So, what would you recommend in this case? Remember, she's currently on bictegravir/FTC/TAF + COBI-boosted darunavir, is now virologically suppressed but has in the background a bunch of resistance mutations as well as the fact that she has hepatitis B virus.

 

We're not seeing any - oh, okay. Yeah, we're not seeing any of the - okay. All right, so before we go to the what if, so what...

 

Dr. Orkin: Well, I think the question is, do you need both? Do you need suspenders as you pull the belt? You called it the -

 

Dr. Kuritzkes: Belt and suspenders.

 

Dr. Orkin: - the belt and suspenders. In the UK, we call it belt and braces.

 

Dr. Kuritzkes: Braces. Right. Of course. Yes.

 

Dr. Orkin: I would say belt or braces. So, I would go either with darunavir, FTC, and - cobicistat/FTC/TAF single tablet, or I would go for bictegravir/FTC/TAF. Or if I was going to use two drugs, I would use TDF/3TC + dolutegravir or TAF/FTC and dolutegravir. But I would use - I would definitely would need the tenofovir to be part of the regimen with an FTC. Yeah.

 

Dr. Gandhi: But this is a good thing to debate, right? Because I was going to say I like darunavir/COBI/TAF/FTC because of all of that data against dolutegravir. It wasn't that the NADIA study didn't show noninferiority. Actually, dolutegravir and darunavir - ritonavir in that case, because this was done in African countries, not darunavir/COBI.

 

With NRTIs, they were noninferior; with NRTI resistance. However, I always think about the fact that there was this low, slow, a little bit of failure, and there was a 4% rate of failure in the dolutegravir arm, and they failed with INSTI mutations. And the people who failed in the darunavir/ritonavir arm failed with NRTI mutations, but it didn't touch the PI. And so, when I compare - and this - again, this is a debate, I think it's a good conversation to have - when I think about the comparison with INSTIs and darunavir boosted with NRTI resistance, and of course they're being put with two NRTIs, I favor darunavir/COBI/TAF/FTC over the INSTIs and the data with BIC/TAF/FTC, as we talked about before, is actually less than it is with the big trials with dolutegravir, but presumably they're equivalent. But those are the B-R-A-A-V-E, BRAAVE 020, and the GS-4030 study. And if you want to look them up. And that was again, history of NRTI resistance and switching over to TAF/FTC.

 

Dr. Orkin: Can I weigh in?

 

Dr. Gandhi: Yes.

 

Dr. Kuritzkes: Please.

 

Dr. Orkin: So, I'm going to weight in to say I completely agree with what you're saying, but it's almost identical scenario as cabotegravir/rilpivirine, okay? Because there was a small risk of virological failure. Well, in this case, the virological failure is similar, but it's virological failure with resistance. Okay? But we're trying to avoid the drug interactions, liabilities, the lipids on the PI. So, I guess, you know, we're back in the same situation. There's a small appreciable risk. And it comes down to, you know, the decision-making, the shared decision-making with the patient. You know, we could go with 100% robust. You know, absolutely no virological failure if you're going to take your darunavir. But that may mean that you then have drug interactions. That may mean that your lipids will be higher, your risk. We know that the risk of - of inflammaging is - is an issue in HIV. You know, there's pros and cons, you know, what do you think?

 

Dr. Kuritzkes: Well, I was going to say also the - well, first of all, I think we're really constrained in this case because of the presence of hepatitis B. So, although one might otherwise think about a variety of two-drug options now that she's been suppressed for two years, that might work just fine. None - as pointed out earlier, none of them include tenofovir, and so that's sort of off the table. I would note that for those countries in which the single tablet of darunavir/cobicistat/FTC/TAF is available, it's a rather sizeable pill. And so, that would be another consideration. Is this a pill that the patient is comfortable taking, or would they be more comfortable with a smaller pill, which would be as a single-tablet regimen bictegravir/FTC/TAF? And you know, with - and we - presumably the risks of resistance in the case of failure would be similar with bictegravir as with dolutegravir. But we have simply no data because the NADIA study was done with dolutegravir, not with bictegravir. But among the failures, there were four of individuals who developed dolutegravir resistance, similar failures in the darunavir arm, but no resistance. So, those are considerations. But the pill size might be the biggest consideration here.

 

Dr. Gandhi: It feels like this is such an excellent thing to debate, because we do have these choices. And I think you can go- no, you actually can't go wrong with either. And it just depends. I would say that if she's going to exhibit variable adherence going forward, which she had in the past, past being predictive of the future, that would be even more a reason for me to want her to be on darunavir. But if she's really going to, you know, really into this and going to take the pills every day, then I think we could do that.

 

What If…

 

Dr. Kuritzkes: Yeah. So, this brings us to a slightly different scenario. So, I said we were constrained by the presence of hepatitis B. So, what if this person did not have hepatitis? Had only the 184V, none of the other mutations? Would any of the newer two-drug regimens be suitable?

 

Dr. Orkin: Yeah, LEN would definitely be suitable. And then you could discuss doravirine/islatravir wouldn't be on license because there's resistance, but we could discuss the virological aspects of that.

 

Dr. Kuritzkes: Right. So, here, at least from my perspective, although it is, as we pointed out before, this person had a history of virologic failure and therefore technically is not - it's not within label to recommend DOR/islatravir, there's nothing in the label that excludes the use of doravirine/islatravir in the presence of a 184V mutation.

 

Switch to DOR/ISL: Virologic Suppression at Wk 96 With BL NRTI RAMs in Proviral DNA

 

And we actually have some data from - that were presented at the AIDS Conference in Rio de Janeiro in - over the summer, which was a retrospective analysis of nearly 1,300 adults who were virologically suppressed and switched to DOR/ISL in the randomized phase III trials that were reviewed previously. But these - these are new data about the impact, or lack of impact, of baseline - presence of mutations in the baseline proviral DNA.

 

Surprisingly to my view, for a patient population or a study population that supposedly had no prior history of treatment failure, 20% of them had evidence of NRTI resistance mutations, 11% had major NRTI - NNRTI mutations, and 5% had 184V, which we know circulates at very low levels. This suggests to me that, in fact, perhaps as many as a fifth of the participants had some history of prior treatment failure that they either forgot about, didn't disclose, the records were lost, or whatever. The bottom line is that if you look at the success rates, whether you had NRTI resistance mutations, major NR- NNRTI resistance mutations, or the 184V mutation, your rates of virologic suppression were really outstanding and similar to the rates that were seen in the people who didn't have these mutations, although that data are not - not shown on this slide.

 

So, I think it's controversial at this point because there's this sort of conflict between the fact that technically, the label says you're not supposed to have had prior failure. The data actually show many people probably did have prior virologic failure, and these mutations have no - no impact. Guidelines have yet to incorporate this information fully, and we'll have to see how - how this all shakes out in the future.

 

Dr. Gandhi: And the PK data really supports that meaning islatravir at the dose that it's given, which is 0.25 mg a day at least the PK data looks like it is way above the threshold to suppress an M184V-containing virus. So, this is going to have to evolve with time. The question of what we do with M184V, because just like BIC/TAF/FTC was not approved for anyone with archived M184V. It took a while, and it took time, and it took reanalysis. And then now, that's in the package insert that you can use BIC/TAF/FTC with M184V. So, we're at the beginning of both of these, which is why I think data will come out, will evolve.

 

Case 5

 

Dr. Kuritzkes: All right. Let me hand this back over to Chloe.

 

Dr. Orkin: Thank you very much. So, Case 5 is...

 

Case 5: Regularly Reviewing ART and Patient Preferences

 

Case 5 is - is slightly less provocative than some of the other cases. So, this is a 40-year-old woman from the UK diagnosed with HIV in 2006 at some other clinic; not my clinic. Currently taking dolutegravir/3TC from us, but prior treatment with B/F/TAF, dolutegravir/abacavir/3TC, efavirenz FTC/TDF in the past. Undetectable since her treatment initiation. No other comorbidities. No other comeds. She is - she has antibodies for hepatitis B and she's core antibody negative.

 

She doesn't plan to conceive, and she's not using any contraceptives.

 

So, basically, it's been a year since her regimen and her preferences were last discussed. And she asks about innovations. She wants to know about any new medications. Now, obviously, in the UK, we don't actually yet have access to BIC/LEN; but we do have access to cabotegravir/rilpivirine.

 

Poll 6

 

And I guess think about it as though you were here, not in the UK. So, she's asking about innovations. She hasn't said specifically about long-acting. She's asked about innovations from - from what she's currently taking. So, please feel free to - to type in any options. But I think we are all very clear on what the new options now, since we've been discussing them the whole evening. But yeah, you can see any option is available, absolutely.

 

So, yeah. So, we see in cabotegravir/rilpivirine whatever options are available. I think that's fair enough. Some people are suggesting we switch it back to bictegravir/FTC/TAF.

 

I think one of the interesting things that definitely struck me in the cabotegravir/rilpivirine studies, particularly the study that I led in the UK called ILANA - it was an implementation study of cabotegravir/rilpivirine - we asked people why they wanted to switch to it. And the most important reason - we asked them for the commonest reasons, but we also asked the most important reason why they were interested in switching to it. And the actual most important reason in our study came up as trying something new.

 

So, I think we think a lot about cabotegravir/rilpivirine or about treatment, innovation, new drugs, about taking away a negative. What sort of negative thing are we going to take away from the person? But there's also a sense of progress that people are interested in novel therapies. They're interested in the future. They're interested in going from three drugs to two. They're interested in injectable options. They are interested in a sense of progress, and I think that is an important feeling that people experience.

 

I'm having some sort of - there we go. So, I don't know what that - was that a poll? Yeah, it was a poll.

 

Poll 6

 

So, we've got type your responses, and then we were going to have the Ask Us Europe.

 

Ask Us Europe: Design

 

So, I mentioned the study earlier. It was a big cross-sectional online survey which we co-produced with community partners in partnership with the European AIDS Treatment Group and the UK Community Advisory Board. And we sat in a room with community members from 18 different countries, and we talked about treatment reviews and the sorts of conversations that - that people are having with their doctor. And together, we designed the survey; we came up with the questions. And anyone who is living with HIV taking treatment, where there was an innovation, which is cabotegravir/rilpivirine. Where it was available was able to participate, and we disseminated the survey via social media, the community and clinical networks.

 

And the first - the biggest question was really about people's perspectives about their clinical consultations. What sort of discussions were they having with their healthcare providers? Who is initiating these discussions? Who felt able to initiate discussions? Who didn't? You know, it was a real equity-focused analysis trying to understand sociodemographic characteristics associated with who has these sorts of conversations.

 

We also asked them about their degree of interest in future modalities. And then we had prespecified subgroup analyses based on lots of different things, lots of different sociodemographic characteristics, but also about their levels of adherence and their levels of need for complex support, and we analyzed the data in all sorts of ways, and we presented it - certainly presented it. We haven't published it yet. We're in the process of that.

 

Ask Us Europe: Treatment Review Discussions Not Happening With the Same Frequency/Consistency for Everyone

 

But our key finding is that basically, treatment review discussions are not happening with the same frequency or consistency for everyone. As I said earlier, 81% of people remembered having some sort of treatment about whether - some sort of discussion about whether their treatment was right for them at some point in their lives. But only 41% remembered a discussion about whether their treatment was right for them in the past year.

 

And among those who did have a discussion about whether their treatment was right for them, only 45% said that cabotegravir/rilpivirine was mentioned. So, they had a discussion about are they on the right treatment? But injectables, which is the only innovation in Europe, was not mentioned.

 

And there were some missed opportunities because among those who didn't discuss cabotegravir/rilpivirine - and it wasn't discussed with them - a lot of people were actually interested in it. So, effectively, we also did 60 interviews in the study. And throughout the interviews, people told us repeatedly that they want to hear about new regimens and they want to hear it from their clinicians.

 

So, I guess the final posttest. I don't know if - does or - does the panel want to come in on this topic? Does anyone want to say anything about the study or thoughts about this before we move to posttest?

 

Dr. Kuritzkes: Well, you know, I think this might be a good opportunity for me to bring in one of the questions from our online viewers, which gets directly to the issues you were just talking about. And that is: how do - how do you approach patients who are not vocal about the challenges that they're experiencing with their regimens?

 

Dr. Orkin: Yeah. Well, I think that - I think if the question - if you don't ask the question, you know, I think those prompts that I was trying to mention in the beginning part, you know, we can say, "Are you satisfied with your regimen? How is your regimen? Is there any way your regimen could be better for you? Are there any problems?" Some people don't like to raise problems. So, you could say - put it in the positive. "Is there any way the regimen could be better for you, more suited to you?" Because not everyone will come and say it, and then we think everything is fine because everything is fine for us. Because basically that means that people - you know, for us, it's very easy if people come every six months, they are undetectable, nothing to worry about, nothing to see here, nothing to do here. But actually, for them, actually, maybe things aren't as good as we - as we think.

 

Dr. Gandhi: I would also say that the stigma question really came up in the SOLAR study. The SOLAR study was switching over from BIC/TAF/FTC to long-acting CAB/RPV. And 47% of people said, "Oh, I didn't even realize that once I switched, I felt less external or internal stigma that people were not watching me get - take my pill every day, or the internal stigma of taking a pill every day and reminding that you have HIV." Like we had in case number one.

 

So, I've had a number of women who, when we discuss it, and they feel like that goes away, that - that it's just sort of, or you can go to the clinic and not have it at home. There was a destigmatization that occurred with this. And I think that is not maybe stressed enough because in every patient-reported outcome in the context of studies, people like the - like in general, people like long-acting.

 

Dr. Orkin: Yeah. And I think as we've seen with the other cases, you know, it's that whole sense of if it ain't broke, don't -let's not fix it. That's our motto. But it's about if it ain't broke for who? You know, it's about thinking, really making sure that we're all on the same page, that everyone, you know, there's - there's no optimization that can be done or offered or discussed. It doesn't mean we have to switch people. A discussion doesn't mean a switch happens; it means that it's an opening, and it's also an information-sharing opportunity. I don't know if there's anything else you wanted to raise, Dan. Okay. Yeah.

 

Dr. Kuritzkes: We can do that in the Q&A.

 

Dr. Gandhi: Oh, yes.

 

Posttest 3

 

Dr. Orkin: Yes. So, the posttest is: For people living with virally suppressed HIV, I plan to regularly discuss whether their current antiretroviral regimen is still the best option for them. Is that:

 

A. Strongly disagree

B. Disagree

C. Neither disagree nor agree

D. Agree, and

E. Strongly agree.

 

Please vote now.

 

Okay. Yeah. Okay. So, I think we can see that we - hopefully, I feel that we've - we've introduced some discussions around reasons to consider regimens for the future. And we can see most people either agreed or strongly agreed that these discussions could take place or should take place.

 

Questions and Answers

 

So, I think we're at the Q&A bit, and there's quite a lot of questions, which is great. So, the online audience and the audience in the room have submitted quite a lot of questions. So, thank you for doing that. I mean, maybe we could take them according to -

 

Dr. Kuritzkes: It's sort of grouped a little bit. Actually, I was going to start maybe with the - there's a question about: when we say no HBV, how confident can you really be that HBV has been completely excluded, since in some of the two drug trials, even after careful screening, there were people who developed HBV?

 

I think it's really critical to distinguish two different factors, right? So, if you have no antibody to HBV, no surface antibody, no core antibody, you do not have hepatitis B virus infection, period. What you might have is you could be at risk for acquiring hepatitis B. I think it's very important to distinguish those two. In people who are core antibody positive, we worry about - if they're taken off a HBV suppressive regimen, we worry about the possibility of reactivation of hepatitis B virus. In people who are hepatitis B virus nonimmune, if they decline vaccination, which should always be offered, then we worry about the risk of acquiring acute hepatitis B virus. And that's - that's a consideration because using a tenofovir and XTC-based regimen is terrific PrEP for protection against hepatitis B.

 

Dr. Orkin: I think there are some uncertainties about the duration of the protection and the levels of the antibodies that are sufficient. And I think people, you know, want to know, like if you have antibodies of - of - of 10, you know, in 2000 and, you know, 2020, is that still protective now? You know, and the question is, when do you - how often should we repeat it? I think they - I think it's reasonable to say that, you know, there are some areas where potentially more, you know, more repeated monitoring of that surface antibodies, if they were low to start with to see whether they've persisted and they remain persistently present. If they were 10, you'd want to know that they were still 10, you know, five years later. We don't know how long the protection lasts. I think monitoring is an important issue.

 

Dr. Gandhi: Yes, especially in reactivations that you don't have only - anything but hepatitis B surface antigen. I think another grouping could be: what about missed doses? And I think this is a good time to ask that question, because the question that was asked here is: someone who's on doravirine/islatravir, is there forgiveness for missed doses? Say they just take five doses and then skip the weekends. And I really wanted to discuss this question because I think we should talk about that with BIC/LEN as well.

 

So, doravirine/islatravir it depends. I mean, drug levels look like, with the doravirine/islatravir dosing, it's 0.25 and 2 milligrams, and it looks like the drug levels are high, and that it would take a while for them to come down. So, we don't have enough data on this, but hoping - hoping it's like other drugs where there's some forgiveness for skipped doses.

 

But I think the reason to even bring up this to also remind us of BIC/LEN in this question as well, because these are such new drugs. BIC/LEN does require the oral loading dose at the beginning of it. What that means is you don't just give someone a prescription for BIC/LEN and have them go on their way. You actually have to give them separately because it's not prepackaged yet. For additional doses of LEN 600 mg on the day they start BIC/LEN and 600 mg the next day. And that's actually two 300-milligram pills. And we have been concerned about that because they have to take the dose the next day, and it doesn't come prepackaged, and we actually have to get the insurance company to pay for the loading doses until they prepackage it.

 

And then there's data at this meeting that's already been released. So, it's going to be a poster on Friday. But this is about looking at the BIC/LEN data in ARTISTRY that it looks like you - if you miss seven doses of the BIC/LEN, you have to reload all over again. So, that, we've been discussing quite a bit with our patient populations who may have difficulty with something complex like that. If they miss seven days, then we'd have to get them in and bring them in and then get them that LEN reloading again. So, I am - I think that's a flaw or a concern that I have about missed doses with LEN.

 

Dr. Orkin: I mean, in the UK, like the idea of people doing weekends off is really not a thing. But in - in Europe, honestly, I'm on the X[?] guidelines, and there's a whole section about people who are taking five days a week therapy in Spain and in France. People are - there's a real, you know, obviously it's not a common thing, but it is something that some people do. So, I think this is an important issue with these two new drugs. And I think, you know, given that this is actually a section in the European guidelines - not a section that I'd be very happy to write, but nonetheless, it's a section - you know, these are important conversations. Yeah.

 

Dr. Kuritzkes: Chloe, there's a question here. Going back to, I think our first case with injectable CAB/rilpivirine we talked about. It's the ability to use it in people who had BMIs greater than 30. What about somebody at a BMI of 40 or 45?

 

Dr. Orkin: Well, the Maguire cohort that I mentioned, he had strata of - or she. I don't know who Maguire is actually, but -

 

Dr. Orkin: They had - it was 30+ and then there was - it was 40+ and 50+. And there was a cohort. It wasn't a large cohort, but they actually did have people over 40 and over 50. So, there's not enormous - I haven't seen enormous amounts of data over 40, but there is this cohort showing that the outcomes were similar, and it was across the different strata.

 

Dr. Gandhi: And you mentioned the OPERA cohort. They did have people hire them as well, but not more than 50.

 

Dr. Orkin: Not as many. Yeah.

 

Dr. Gandhi: And then I would also say that I always looked at the LATITUDE study, the A5359 study, which showed CAB/RPV works in - better in those with adherence challenges, published in The New England Journal last February. But there, they keep on defining failures that are coming out as they're following them. And there doesn't seem to be rhyme or reason that they have high weights. So, it's looking to the failures, you know, across studies and looking at the failures, not seeing that high weight is associated.

 

Dr. Orkin: Yeah. And it's important also to say that in the CARES study, which was in three sub-Saharan African countries, which would be the same - which are the same. South Africa is one of the countries, the same country of the ADVANCE study, which is when the women are very, very large, you know, one-fifth of them, 1 in 5, had a BMI greater than 30 in the CARES study. And when we say in those women, it's not going to be BMI of 30; it's going to be a lot higher than that. Yeah.

 

Dr. Gandhi: Yeah. I think this is such a good question I'll ask because this is - this came up on - when, you know, these drugs had just been approved at CROI, that all the data was coming out. So, there was this excellent discussion of when would you - would you take someone off BIC/TAF/FTC for renal protection? You know, is there going to be a reason? And I would say we may all have different ideas on this that someone's older, they have renal risk factors, but they don't have renal insufficiency yet. Are you going to want them - and they don't have hepatitis B? Do you want to move them on to doravirine/islatravir or BIC/LEN for renal protection itself? And I'll just answer that first and see what you both say. Because I - I would say yes, but that happened to be because I have a large number of women in my practice because that's how I started, and I've seen some ill effects of even TAF with bone and renal as - as time marches on. So, I do think about renal even protection later. And I would say that I think also tenofovir levels accumulate. The tenofovir diphosphate level accumulates with TAF as your renal function goes down, so that strict criteria that you can use to half down to less than 30. I'm not comfortable with 40.

 

Dr. Kuritzkes: So, I think this really boils down to a sort of clinical judgement and clinical practice issue because there are no data. Right? I mean, although I think we know generally that incidence of bone mineral loss and of renal injury in people on TAF is much lower than people on TDF. But episodes of frank failure were no different in the clinical trials, because the clinical trials were neither long enough nor large enough to be able to see differences in terms of clinical endpoints, such as progression to renal failure, occurrence of renal tubular acidosis, or - or actual fracture. So, I would say it really depends. If somebody was having declining renal function, particularly if they had evidence on urinalysis of - of phosphate wasting or of glycosuria and other signs of tubular dysfunction, I would be inclined to switch them. If they were doing fine, I don't think there are data to support a proactive switch, and I would keep them on their regimen as long as they're happy being on that regimen.

 

Dr. Orkin: Yeah, I mean, I agree. I think it's a data gap, and I think there's biological plausibility that tenofovir is an issue. But equally, if someone's doing just as well and, you know, evidence is also growing that you can use TAF down to lower levels. I think it's a - it's a - it's a whole person issue. And again, it's a shared decision-making discussion, but it's definitely something to be considered. And I think, you know, it's an important consideration. So, there's been some - there's quite a few - well, there's two questions about M184V.

 

So, someone has asked: if someone has M184V at baseline and diagnosis, would you consider this patient for DOR/ISL? So, that's the first - that's the first one. And then is there a difference if it's in proviral DNA versus measured?

 

Dr. Kuritzkes: Yeah. So, let me take the second question first because I think there is a very clear difference. If - if somebody has a 184V in their circulating virus, then first of all, they've either recently acquired that virus or have had some recent exposure to 3TC or FTC, and I would be very concerned that in that circumstance, we don't really have evidence that initiating a regimen with islatravir in people, at least, will be as effective. And that would be clearly off-label, and I would avoid its use in that circumstance.

 

In the - the first question, the person who had a 184V but suppressed on a bictegravir/FTC tenofovir-containing regimen, then I think it becomes a matter of time. We know that with dolutegravir/3TC, there have been several studies that show that the longer an individual has been suppressed from the time a 184V was last documented, the lower the risk that there's going to be failure if they switch to dolutegravir/3TC, particularly after a couple of years. And so, if somebody is - if that person who started on a bictegravir-based regimen was suppressed for six or more months, I would then begin to feel much more comfortable about switching them to an islatravir-containing regimen despite the original presence of the 184V mutation.

 

Dr. Gandhi: I think one thing - one trial that speaks to what you just said is the CARES study. So, in the CARES study, which is again switching over from - we've mentioned this three times, Uganda, Kenya, South Africa, switching over from your oral ART to CAB/RPV if you're virologically suppressed, and of course, most people are on dolutegravir-based regimens. They did PBMC HIV DNA genotyping. So, you couldn't do RNA genotyping because everyone was suppressed and they didn't have historic. So, just looking at the PBMCs. And there were NNRTI mutations, there was actually a certain degree of INSTI mutations as well in the PBMCs, in that "archived resistance." That's how you would get it in this case. And it didn't make a difference. There was really high rates of virologic suppression on CAB/RPV, whether you had an archived and an RT mutation or not. So, I think there's a clear difference between having archived resistance and active resistance, or even on historical genotypes.

 

And the CARES data, and again, some of this data, the switchover, we've chosen not to do archived genotyping at our clinic, Ward 86. We also have a low-income population, and we end up having to be charged for it a lot. But it's because we think that we can get it from the historic data.

 

Dr. Orkin: It's funny we - we don't do proviral DNA either because we feel that it can be misleading. It can tell you it's not there, and it is there. So, we present based it on the history.

 

Dr. Orkin: No, I agree.

 

Dr. Gandhi: Like where you find mutations and you don't use something that you would have used otherwise. And it ended up being more difficult. So, we've chosen not to do that.

 

Dr. Orkin: Absolutely. And then, on a related point, there was a person asking, you know, in case three would be if TAF have been a reasonable option, given that, you know, there was archived M184V and TAMs. And I think we covered the fact that we would have used either B/F/TAF or we would have used darunavir/FTC, cobicistat/FTC/TAF. So, we'll take that as answered.

 

Someone's asked about cost of the newer medications and staffing issues with injectables. So, I guess they're saying it's all very well saying you're going to switch, but switches are costly and they - they take time. I think that is true. But I think, you know, in my context, cabotegravir/rilpivirine has been deemed to be cost-effective. So, we're allowed to use it as a switch option, you know, as any - any option if someone is eligible for it. So, we don't - the cost is no different in the UK from my perspective; I'm allowed to use - I'm sorry, I did that again. You're allowed to use it regardless, but obviously there is a capacity issue, and it definitely is the case that the more you do cabotegravir/rilpivirine, the easier it gets to add more additional people, and the better your system gets and the better your monitoring gets and the better everything gets. So, the more you do, the more you're able to do.

 

Dr. Gandhi: That's the same with our clinic. We were - also thought it'd be a very kind of complicated thing, but we kept in thinking all of the planets[?] switch from efavirenz to dolutegravir, and they did it. And so, we - the way what we did with injectables is we had a champion. I think a clinical champion is really important. And then we just did it, and then it became routine. So, now we have three nurses who always inject. They do it every third day. We give about 20 injections a day. We have a fourth of our clinic on long-acting CAB/RPV. We have kind of an ART. Now that we take it out of the fridge, we - we've texted them and said, "Come in," and we take it out, and we're ready, and we get them in and out in 30 minutes. We use ice for lenacapavir. We kind of have this whole strategy now, and it's - it's pretty seamless now, but it took a while to get up there.

 

Dr. Orkin: There's a question about how do you compare dolutegravir/rilpivirine versus doravirine/islatravir in early CKD? I mean...

 

Dr. Gandhi: One thing we have to remember is dolutegravir will increase, you know, INSTIs inhibit the tubular secretion of creatinine. So, there'll be this artificial rise in creatinine that can happen with BIC and any INSTI. So, I always - people can get nervous about that. But in terms of their renal safety profiles, I would say they're equivalent. I don't think they're - we don't have a head-to-head comparison, but neither - they are neither - any of those four drugs are in the criteria of hurting the kidney.

 

Dr. Orkin: Well, we're one minute away from the end of the symposium. And there's a final question. We all know who it's going to. And the final question is, with - and I definitely would not answer this question: With all of the different medications to help treat HIV, do you think there will ever be a cure? And that is going to Dr. Kuritzkes.

 

Dr. Kuritzkes: That is a topic for an entirely different symposium. I think at this point it's very hard to say. There's an enormous amount of work that's being done and that's been done, but we really are very far away still from a cure.

 

Dr. Orkin: I have to say, I agree with the second part for sure. So, thank you very much to my wonderful co-faculty; I've really enjoyed chatting with you, and to the wonderful in-person and online audience for all your questions and engagement.

 

Go Online for More Coverage of HIV!

 

Please go online for more coverage and the downloadable slides of all the key data, as well as on-demand webcasts for all the key studies. And you can find it over there. And thank you for your engagement, and have a good evening.

 

Dr. Kuritzkes: Thank you.

 

[END OF TRANSCRIPT]